^
    Back
    Association details:
    Biomarker:STRN-ALK fusion
    Cancer:Lung Adenocarcinoma
    Drug:Alecensa (alectinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Onco Targets Ther
    Title:

    STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review

    Published date:
    12/04/2020
    Excerpt:
    A 64-year-old Chinese male...was diagnosed as stage IVB lung adenocarcinoma (LADC) (cT4N3M1c) in October 2018. Next-generation sequencing (NGS)...revealed an STRN-ALK fusion. The patient received alectinib...with an excellent response exceeding 19 months.
    DOI:
    10.2147/OTT.S282933